Cortellini, A., Brunetti, L., Di Fazio, G., Garbo, E., Pinato, D., Naidoo, J., . . . Ricciuti, B. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry.
Citação norma ChicagoCortellini, A., et al. Determinants of 5-year Survival in Patients With Advanced NSCLC With PD-L1=50% Treated With First-line Pembrolizumab Outside of Clinical Trials: Results From the Pembro-real 5Y Global Registry. 2025.
Citação norma MLACortellini, A., et al. Determinants of 5-year Survival in Patients With Advanced NSCLC With PD-L1=50% Treated With First-line Pembrolizumab Outside of Clinical Trials: Results From the Pembro-real 5Y Global Registry. 2025.